Current News

Print version | PDF version | Send article | RSS-Feed

BAC appoints Dr Andrew Carr as Chairman of Supervisory Board

30 Jan 2008 - BAC BV, the Bio Affinity Company, announced the appointment of Dr Andrew Carr as Chairman to its Supervisory Board.
 
Dr Carr brings a wealth of experience in the biotech industry to the role. As CEO of Amersham Biosciences and a Director of Amersham plc, Dr Carr played a key role in growing the Life Science Research and Bio-separations business units until the successful acquisition of Amersham by GE Healthcare in 2004. Dr Carr is currently a Non-executive Director and Chairman of several European private equity funded companies and has been involved in raising finance and execution of third party deals.
 
Dr Carr is currently Chairman of deltaDOT Ltd and Teraview Ltd, a Director of SciBridge Ltd, and an advisor to SpinX-Technologies SA. He is also a member of the Imperial Innovations investment advisory group. Dr Carr has a PhD in Zoology from the University of Nottingham.